Clinical Trials Logo

Sclerosis clinical trials

View clinical trials related to Sclerosis.

Filter by:

NCT ID: NCT04220021 Active, not recruiting - Clinical trials for Frontotemporal Dementia

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

Start date: January 10, 2020
Phase: Phase 2
Study type: Interventional

The primary objective is to assess the safety and tolerability of Metformin in subjects with C9orf72 amyotrophic lateral sclerosis administered for 24 weeks. The overall objective is to determine if Metformin is safe in C9orf72 ALS patients and is a potentially viable therapeutic treatment for C9-ALS that reduces repeat-associated non-canonical start codon - in DNA (non-ATG) (RAN) proteins that are produced by the C9orf72 repeat expansion mutation.

NCT ID: NCT04219592 Active, not recruiting - Systemic Sclerosis Clinical Trials

IgG-4 Levels in Systemic Sclerosis

SSc-IgG4
Start date: May 30, 2019
Phase:
Study type: Observational

This is an observational - non interventional study. The investigators will compare IgG4 levels of 80 healthy donors (from Israel blood bank - MDA) and 80 Systemic Sclerosis patients from Meir Medical Center.

NCT ID: NCT04206644 Active, not recruiting - Systemic Sclerosis Clinical Trials

Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages

SCLERO JAK
Start date: January 21, 2021
Phase:
Study type: Observational

The Sclero-JAK project aims to assess the impact of a JAK1/2 inhibitor (ruxolitinib) on activation states of monocytes-derived macrophages (MDM) from systemic sclerosis (SSc) patients

NCT ID: NCT04140305 Active, not recruiting - Multiple Sclerosis Clinical Trials

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

ENLIGHTEN
Start date: January 16, 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years. All subjects will receive orally administered ozanimod HCl 1 mg. The primary efficacy endpoint is the proportion of subjects with a clinically meaningful increase in raw score of ≥ 4 points or 10% from baseline (improved). The treatment period is 36 months. For all subjects who finish the subject and for those who discontinue, there will be a 30-day (± 15 days) and a 90-day (± 10 days) Safety Follow-up Visit. There is no planned protocol extension following the end of the study. Approximately 250 subjects with RMS will be recruited for this study. Subjects with RMS will be enrolled in this study if they have received ≤ 1 DMT, have an EDSS ≤ 3.5, and have been diagnosed with RMS within 5 years of study entry. The Investigator will be responsible for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS relapses, and management of AEs.

NCT ID: NCT04132167 Active, not recruiting - Multiple Sclerosis Clinical Trials

Supervised Perturbation Training Results in Changes in Balance and Falling in Patients With Multiple Sclerosis

Start date: November 20, 2018
Phase: N/A
Study type: Interventional

Physical exercise can prevent falls, certain types of exercise may be more effective. Perturbation-based balance training is a novel intervention involving repeated postural perturbations aiming to improve control of rapid balance reactions. The purpose of this study was to estimate the effect of perturbation- based balance training on falls and balance in daily life.Thirty patients with multiple sclerosis (PwMS) will assess with regard to dynamic balance, walking and falling. Patients randomly will allocate to a personalized (PRG) or traditional (TRG) rehabilitation group.

NCT ID: NCT04132037 Active, not recruiting - Multiple Sclerosis Clinical Trials

An Observational Study on Intermittent Self Catheterisation Discontinuation Factors in Multiple Sclerosis Patients

SEPAS
Start date: June 26, 2019
Phase:
Study type: Observational

Urinary disorders (UD) are common in Multiple Sclerosis (MS) and can necessitate using Intermittent Self Catheterisation (ISC). It is well experienced by patients, has little impact on daily life and improves quality of life. However, studies are lacking on long-term adherence to this treatment as well as on discontinuation factors. Our main objective is to prospectively assessed factors associated with ISC discontinuation 2 years after having introduced this technique.

NCT ID: NCT04130997 Active, not recruiting - Clinical trials for Relapsing Multiple Sclerosis (RMS)

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Start date: November 18, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).

NCT ID: NCT04112537 Active, not recruiting - Clinical trials for Tuberous Sclerosis Complex

Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship

Start date: March 1, 2019
Phase:
Study type: Observational

Tuberous Sclerosis is a rare genetic disorder that affects about one in 15,000 individuals. It is part of the phacomatoses: a germline mutation of the gene Tuberous Sclerosis Complex 1 (TSC1) or TSC2 causes a protein dysfunction, hamartin and tuberin respectively, leading to mTOR signaling pathway activation, thus tumors rise on the skin but also brain, eyes, kidneys, heart. Thanks to the advent of sequencing techniques of the human genome, genes involved were found twenty years ago. Most commonly, these are de novo private mutations and autosomal dominant Mendelian transmission. About 15% of patients have a phenotype corresponding to the disease but no mutation is found. Although the initial clinical description was in 1880, publications regularly describe new signs in Tuberous Sclerosis, especially for skin. Cutaneous manifestations are important in the diagnostic criteria of the disease and often even the first sign of appeal. However, no data is available on the relationship between genotype and dermatological phenotype. Therefore the investigator intend to review all cutaneous finding in Tuberous Sclerosis patient and try to link with their mutation.

NCT ID: NCT04100525 Active, not recruiting - Multiple Sclerosis Clinical Trials

Intervention for Employed Women With Multiple Sclerosis

Start date: April 2016
Phase: N/A
Study type: Interventional

Unemployment is particularly common among women with multiple sclerosis (MS). This study uses a vocational rehabilitation program involving neuropsychological testing as an intervention. The use of in-person feedback and case management following neuropsychological testing is compared to phone feedback only. Adherence to treatment and employment outcomes will be evaluated over three years.

NCT ID: NCT04096443 Active, not recruiting - Multiple Sclerosis Clinical Trials

Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis

Start date: October 28, 2019
Phase: Early Phase 1
Study type: Interventional

The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS). The investigators plan to gather preliminary data in a small cohort of 10 to 15 adults with MS.